Background and Rationale

Hereditary ATTR (hATTR) Amyloidosis with Polyneuropathy
• Inherited, rapidly progressive, life-threatening disease due to a mutation in the transthyretin (TTR) gene, causing misfolded TTR proteins to accumulate as amyloid fibrils in multiple organs, including the nerves, heart, and gastrointestinal tract • Multisystemic disease with a heterogeneous clinical presentation, including sensory, motor and autonomic neuropathy, and cardiac dysfunction • With disease progression, symptoms increase in severity, leading to significant morbidity, disability, decreased quality of life, loss of physical function, and death • Aggressive course can lead to mortality within 2-15 years of disease onset • Limited treatment options exist, thus high unmet medical need for novel therapeutics remains
Patisiran
• An investigational RNA interference (RNAi) therapeutic in development for the treatment of hATTR amyloidosis • Early clinical development demonstrated potent, robust, and rapid knockdown of mutant and wildtype TTR in healthy volunteers and in patients with hATTR amyloidosis 1,2
• hATTR amyloidosis represents a major unmet medical need requiring early and accurate diagnosis for optimal management due to rapid and irreversible progression of disease • Data further demonstrate that patients with hATTR amyloidosis experience considerable burden of illness early in the disease course and this burden increases with disease progression • Dataset represents the largest controlled study of patients with hATTR amyloidosis with polyneuropathy and includes a globally representative population and a wide range of TTR mutations and disease severity
Methods
Phase 3 APOLLO Study Design
• Randomized, double-blind, placebo-controlled, global study designed to evaluate the efficacy and safety of patisiran in patients with hATTR amyloidosis with polyneuropathy • APOLLO trial utilized to collect patient-reported Euro Quality of Life -5 Dimension (EQ-5D), Norfolk QOL -Diabetic Neuropathy (QOL-DN), Rasch-built Overall Disability Scale (R-ODS), and healthcare resource utilization Scales used to assess burden of disease:
Patient Population
• Norfolk QOL-DN: range, -2 to 138 (scores increase with symptom severity)
• Euro Quality of Life -5 Dimension (EQ-5D) score: range, 0 (death) to 1 (best possible health) • Euro QOL Visual Analog Scale (EQ-VAS) score: range, 0 (worst health) to 100 (best health)
• Rasch-Built Overall Disability Scale (R-ODS) score: range, 0 (greatest disability) to 48 (no limitations)
